Client Success

Client: AffyImmune Therapeutics
AffyImmue Therapeutics, a clinical-stage biotechnology company committed to developing its novel, first-in-class ICAM-1 targeting chimeric antigen receptor (CAR) T cell therapy for solid tumors, today announced the appointment of Deyaa Adib, M.D., as Chief Medical Officer (CMO).…

Client: ArrePath, Inc.
ArrePath, Inc., an emerging biotechnology company focused on applying deep phenotypic insights and machine learning to the discovery of new anti-infectives, today announced the appointment of Kevin Krause as President and Chief Executive. Mr. Krause brings more…

Client: SpeeDx
SpeeDx, a leading innovator in molecular diagnostic solutions, today announced the appointment of Jeremy Stackawitz as Chief Executive Officer. With more than 25 years of leadership experience in the life sciences and diagnostics sectors, Stackawitz will focus on accelerating SpeeDx's…

Client: Nusano, Inc.
Nusano, Inc., a physics company transforming the production of medical radioisotopes, today announced the addition of two executives to support its business commercialization and the availability of non-carrier-added lutetium-177 (n.c.a. Lu-177) beginning in 2025.
Joining Nusano are…

Client: Abeona Therapeutics
Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the appointment of Bernhardt G. Zeiher, MD, FCCP, FACP, and Eric Crombez, MD as new independent members to its Board of Directors. Dr. Zeiher brings more than 20 years of…

Client: Fennec Pharmaceuticals
RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced the appointment of Mr. Jeff Hackman as its Chief Executive Officer (CEO) and a member of the Board…

Client: Cleveland Diagnostics, Inc.
Cleveland Diagnostics, Inc., a cancer biotechnology company, today announced the appointment of a new independent director, Dara Grantham Wright, to its Board of Directors. Wright’s extensive experience in life science research and clinical diagnostics will be an…

Client: AffyImmune
AffyImmune, a clinical-stage biotechnology company committed to developing novel, first-in-class CAR T cell therapies, today announced the appointment of Daniel Janse, Ph.D. as President and Chief Executive Officer. Dr. Janse brings twenty years of expertise and an extensive…

Client: AxoSim
AxoSim, a life science company building human brains in the lab at scale to heal memory, movement, and pain disorders, today announced the appointment of Alif Saleh as chief executive officer. With this appointment, co-founder and previous CEO…